Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice

Pharmacological Reports

Volumn 61, Issue 2, 2009, Pages 252-260

  Łuszczki, Jarogniew J ^a,b   Czernecki, Remigiusz ^a,c   Dudra Jastrzebska, Monika ^a,b   Borowicz, Kinga K ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c Neuropsychiatric Hospital Kielce   (Poland)

Author keywords

Agmatine; Antiepileptic drugs; Drug interactions; Pentetrazole induced seizures; Vigabatrin

Indexed keywords

AGMATINE; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; PHENOBARBITAL; TIAGABINE; VALPROIC ACID; VIGABATRIN; ANTICONVULSIVE AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLONIC SEIZURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; SEIZURE; SWISS WEBSTER MOUSE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG INTERACTION;

AGMATINE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; PENTYLENETETRAZOLE; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; VIGABATRIN;

EID: 67650237081     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70029-5     Document Type: Article

References (44)

1. Abe K, Abe Y, Saito H: Agmatine suppresses nitric oxide production in microglia. Brain Res, 2000, 872, 141-148.
2. Auguet M, Viossat I, Marin JG, Chabrier PE: Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol, 1995, 69, 285-287.
3. Bence AK, Worthen DR, Stables JP, Crooks PA: An in vivo evaluation of the antiseizure activity and acute neurotoxicity of aginatine. Pharmacol Biochem Behav, 2003, 74, 771-775.
4. Blantz RC, Satriano J. Gabbai F, Kelly C: Biological effects of arginine metabolites. Acta Physiol Scand, 2000, 168, 21-25.
5. Borowicz KY, Łuszczki J, Kleinrok Z, Czuczwar SJ: 7-Nitroindazole, a nitric oxide synthase inhibitor, enhances the anticonvulsive action of ethosuximide and clonazepam against pentylenetetrazol-induced convulsions. J Neural Transm, 2000, 107, 1117-1126.
6. Czuczwar SJ, Tutka P, Klonowski P, Kleinrok Z: N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. Eur J Pharmacol, 1999, 366, 137-142.
7. de Krom MC, Verduin N, Visser E, KIjejer M, Scboltes F, De Groen JH: Status epilepticus during vigabatrin treatment: a report of three cases. Seizure, 1995, 4, 159-162.
8. Demady DR, Jianmongkol S, Vuletich JL, Bender AT, Osawa Y. Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol, 2001, 59, 24-29.
9. Demehri S, Homayoun H, Honar H, Riazi K, Vafaie K, Roushanzamir F, Dehpour AR: Agmatine exerts anticonvulsant effect in nuce: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology, 2003, 45, 534-542.
10. Feng Y, LeBlanc MH, Regunathan S: Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anti-convulsive effects. Neurosci Lett, 2005, 396, 129-133.
11. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ: Inhibition of mammalian nitric-oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J, 1996, 316, 247-249.
12. Garthwaite J, Charles SL, Chess-Williams R: Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature, 1988, 336, 385-388.
13. Genton P: When antiepileptic drugs aggravate epilepsy. Brain Dev, 2000, 22, 75-80.
14. Gibson DA, Harris BR, Rogers DT, Littleton JM: Radio-ligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil. Brain Res, 2002, 952, 71-77.
15. Gilad GM, Salame K, Rabey JM, GiladVH: Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci, 1996, 58, PL41-PL46.
16. Gonzalez C, Regunathan S, Reis DJ, Estrada C: Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharmacol, 1996, 119, 677-684.
17. Holt A, Baker GB: Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Prog Brain Res, 1995, 106, 187-197.
18. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ: gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem, 1977, 29, 797-802.
19. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ: Agmatine: an endogenous clonidine-displacing substance in the brain. Science, 1994, 263, 966-969.
20. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
21. Löscher W: Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol, 1998, 54, 721-741.
22. Löscher W, Schmidt D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res, 1988, 2, 145-181.
23. Łuszczki JJ, Czernecki R, Wojtal K, Borowicz KK, Czuczwar SJ: Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm, 2008, 115, 1485-1494.
24. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373, 169-181.
25. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Pharmacodynamic and/or pharmacokinetic characteristics of interactions between foreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Epilepsy Behav, 2005, 7, 639-651.
26. Łuszczki JJ, Szadkowski M, Czuczwar SJ: Effect of NG-nitro-L-arginine on the onticonvulsant action of four second-generation antiepileptic drugs in pentetrazole-induced clonic seizures in mice. Pharmacol Rep, 2007, 59, 467-473.
27. Łuszczki JJ, Wójcik-Ćwikła J, Andres MM, Czuczwar SJ: Pharmacological and behavioral characteristics of interattions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 2005, 30, 958-973.
28. Morrissey JJ, Klahr S: Agniatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians, 1997, 109, 51-57.
29. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpcio Boronat M, Trullas R, Villarroel A et al.: Protection by imidazol(ine) drugs and agmatine of glutamate-induced nedotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol, 1999, 127, 1317-1326.
30. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol, 2003, 2, 347-356.
31. Perucca E, Gram L, Avanzini G, Dulac O: Antiepileptic drugs as a cause of worsening seizures. Epilepsia, 1998, 39, 5-17.
32. Piletz JE, May PJ, Wang G, Zhu H: Agmatine crosses the blood-brain barrier. Ann NY Acad Sci, 2003, 1009, 64-74.
33. Raasch W, Schäfer U, Chun J, Dominiak P: Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol, 2001, 133, 755-780.
34. Rambeck B, Sprecht U, Wolf P: Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet, 1996, 31, 309-324.
35. Reis DJ, Regunathan S: Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci, 2000, 21, 187-193.
36. Riazi K, Honar H, Homayoun H, Rashidi N, Kiani S, Ebrahimkhani MR, Noorian AR et al.: The synergistic anticonvulsant effect of agmatine and morphine: possible role of alpha 2-adrenoceptors. Epilepsy Res, 2005, 65, 33-40.
37. Sastre M, Regunathan S, Galea E, Reis DJ: Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J Neurochem, 1996, 67, 1761-1765.
38. Striano P, Coppola A, Madia F, Pezzella M, Ciampa C, Zara F, Striano S: Life-threatening status epilepticus following gabapentin administration in a patient with be- nign adult familial myoclonic epilepsy. Epilepsia, 2007, 48, 1995-1998.
39. Su RB, Wei XL, Zheng JQ, Liu Y, Lu XQ, Li J: Anticonvulsive effect of aginatine in mice. Pharmacol Biochem Behav, 2004, 77, 345-349.
40. Szabo C: Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res Bull, 1996, 41, 131-141.
41. Thomas P, Valton L, Genton P: Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain, 2006, 129, 1281-1292.
42. Walker BR, Easton A, Gale K: Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Epilepsia, 1999, 40, 1051-1057.
43. Weng XC, Gai XD, Zheng JQ, Li J: Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons. Acta Pharmacol Sin, 2003, 24, 746-750.
44. Yang XC, Reis DJ: Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther, 1999, 288, 544-549.